STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1/2	Title page
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3/47	Abstract
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	5/94	Introduction/ Paragraph 1 and 2
Objectives	3	State specific objectives, including any prespecified hypotheses	6/117	Introduction/ Paragraph 3
Methods				
Study design	4	Present key elements of study design early in the paper	6/123	Methods/Study design and population/Paragraph 1
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6/123	Methods/Study design and population/Paragraph 1
Participants	6	(a) ***Cohort study***—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up ***Case-control study***—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls ***Cross-sectional study***—Give the eligibility criteria, and the sources and methods of selection of participants	6/125	Methods/ Study design and population/ Paragraph 1
		(b) ***Cohort study***—For matched studies, give matching criteria and number of exposed and unexposed ***Case-control study***—For matched studies, give matching criteria and the number of controls per case	N/A	No comparison group
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7/142	Methods/ Outcomes and statistical analysis/ Paragraph 1
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6/132	Methods/Study design and population/ Paragraph 1
Bias	9	Describe any efforts to address potential sources of bias	6/127, 7/53	Methods/Study design and population/Paragraph 1
Study size	10	Explain how the study size was arrived at	N/A	All patients meeting criteria were included
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6/132	Methods/Study design and population/ Paragraph 1

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7/142	Methods/Outcomes and Statistical analysis
		(b) Describe any methods used to examine subgroups and interactions	N/A	No subgroups were analyzed
		(c) Explain how missing data were addressed	N/A	Patients with missing data on inclusion criteria were excluded
		(d) ***Cohort study***—If applicable, explain how loss to follow-up was addressed ***Case-control study***—If applicable, explain how matching of cases and controls was addressed ***Cross-sectional study***—If applicable, describe analytical methods taking account of sampling strategy	7/148	Methods/Outcomes and Statistical analysis/ Paragraph 1
		(e) Describe any sensitivity analyses	N/A	No sensitivity analysis was conducted
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6/131	Figure 1
		(b) Give reasons for non-participation at each stage	6/131	Figure 1
		(c) Consider use of a flow diagram	6/131	Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7/159	Results/ Patient characteristics/Paragraph 1
		(b) Indicate number of participants with missing data for each variable of interest	N/A	No missing data on baseline characteristics
		(c) ***Cohort study***—Summarise follow-up time (eg, average and total amount)	8/164	Results/ Patient characteristics/Paragraph 1
Outcome data	15*	***Cohort study***—Report numbers of outcome events or summary measures over time	8/174	Results/Patient outcomes/ Paragraph 1
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	N/A	This is a cohort, longitudinal study
		Cross-sectional study—Report numbers of outcome events or summary measures	N/A	This is a cohort, longitudinal study
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	8/174	Results/Patient outcomes/ Paragraph 1 and 2
		(b) Report category boundaries when continuous variables were categorized	Table 1 and 2	Category boundaries for any variable shown in Table 1/2
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A	No relative risk reported
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	9/186	Results/Patient outcomes/ Paragraph 2
Discussion				
Key results	18	Summarise key results with reference to study objectives	9/190	Discussion/Paragraph 1
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13/282	Discussion/Paragraph 9

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	13/295	Conclusion
Generalisability	21	Discuss the generalisability (external validity) of the study results	13/290	Discussion/ Paragraph 9
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	14/323	Funding sources

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article information: https://dx.doi.org/10.21037/atm-24-85
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.